Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02804711
Other study ID # JSVCT027
Secondary ID
Status Completed
Phase Phase 1
First received June 11, 2016
Last updated October 14, 2017
Start date September 2016
Est. completion date September 2017

Study information

Verified date October 2017
Source Jiangsu Province Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Before this study, there will be an open-label, dose-escalation pilot study with a total of 30 participants with 10 per dosage group. The aim of the pilot study is to explore the preliminary safety of an experimental recombinant staphylococcus aureus vaccine.

This is a single center, double-blind, placebo control, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile, and immunogenicity of an experimental recombinant staphylococcus aureus vaccine. The study will be carried out following a dose-escalation method from the low dosage to the high dosage, i.e. the higher dosage vaccine could only be administrated after the first seven-day safety of the lower dosage vaccine is confirmed after safety observation.


Recruitment information / eligibility

Status Completed
Enrollment 144
Est. completion date September 2017
Est. primary completion date July 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Healthy volunteers aged 18 to 65 years (aged over 18 and under 66 years).

- Able to comply with all clinical trial protocol requirements and willing to complete all the visit plan process during the whole clinical trial observation period.

- Able to understand the content of informed consent and willing to sign the informed consent.

- Able to complete the diary card independently.

- For females only (18-49 years), a negative urine pregnancy test and willing to practice continuous effective contraception during the study.

- Axillary temperature =37.0°C.

Exclusion Criteria:

First Immunization exclusion standard:

- Prior receipt of Staphylococcus aureus vaccine

- Any confirmed Staphylococcus aureus infection disease in the past 12 month.

- History of asthma, hereditary angioneurotic edema, diabetes, malignancy or other serious disease. Participation in the clinical trial is likely to increase the disease risk and interfere with the observation of clinical trial index.

- Prior blood donation or Blood loss over 400ml in the last 3 months;

- Coagulation disorders (coagulation factor deficiency, coagulopathy or platelet disorder) diagnosed by doctors, or obvious bruises or blood coagulation noticed.

- History of allergic disease likely to be exacerbated by any component of the vaccine, including allergy, urticaria, respiratory difficulty, angioneurotic edema or abdominal pain.

- Any autoimmune disease or immunodeficient state, parents, brother and sister with autoimmune disease or immunodeficient disease.

- Taking immunoglobulins and/or any blood products within the last 12 months.

- Asplenia, functional asplenia or asplenia caused by any situation or splenectomy.

- Any acute disease or acute attack of chronic disease in last 7 days.

- History of thyroidectomy or thyroid disease requiring treatment in the last 12 months.

- Immunosuppressor, cytotoxic therapy, inhaled corticosteroid (excluding corticosteroids spray treatment of allergic rhinitis, acute and non-concurrent corticosteroids treatment)

- Participation in another research study involving receipt of an investigational product in the last 30 days.

- Woman who is breast-feeding.

- Prior administration of attenuated vaccine in last 28 days.

- Prior administration of subunit vaccine, inactivated vaccine or allergic therapy in last 14 days.

- Current anti-tuberculosis prophylaxis or therapy

- Any other conditions may compromise the safety or availability of participants in the judgment of the investigator.

Following Immunization exclusion standard:

- Any grade 3 or more serious adverse reaction happen since the last vaccination.

- Other condition violates the inclusion criteria or meets the exclusion criteria is noticed after the first immunization.

- Acute or chronic infections at the vaccination day (axillary temperature>37.0°C).

- According to the investigator, the participant should not continue participating in the study.

Study Design


Intervention

Biological:
Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)

Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)

High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)

Placebo


Locations

Country Name City State
China Xiaokui Hu Taixing Jiangsu

Sponsors (3)

Lead Sponsor Collaborator
Jiangsu Province Centers for Disease Control and Prevention Chengdu Olymvax Biopharmaceuticals Inc., Third Military Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes of the colonization of Staphylococcus aureus on nasal mucosus after vaccination. Changes of the colonization of Staphylococcus aureus on nasal mucosus after vaccination with the Staphylococcus aureus vaccine at day at day 3, 7, 10, 14, 17, 21, 42 and month 3, 6. within 6 months after the vaccination
Other Specific functional antibody responses to the Staphylococcus aureus vaccine Specific functional antibody responses to the Staphylococcus aureus vaccine at day 7, 14, 21, 42 and month 3, 6. within 6 months after the vaccination
Other Specific T cell immune responses to the Staphylococcus aureus vaccine. Specific T cell immune responses to the Staphylococcus aureus vaccine at day at day7, 14, 21, 42 and month 3, 6 measured by ELISpot. within 6 months after the vaccination
Primary Occurrence of injection site adverse reactions after vaccination Occurrence of solicited injection site adverse reactions within 21 days after vaccination with the Recombinant Staphylococcus aureus vaccine within 21 days after the vaccination
Primary Occurrence of systematic adverse reactions after vaccination Occurrence of solicited systematic adverse reactions within 21 days after vaccination with the Recombinant Staphylococcus aureus vaccine within 21 days after the vaccination
Secondary Occurrence of unsolicited adverse reactions after vaccination. Occurrence of unsolicited adverse reactions within 42 days after vaccination with the Recombinant Staphylococcus aureus vaccine within 42 days after the vaccination
Secondary Occurrence of serious adverse events after the vaccination. Occurrence of serious adverse events within 6 months after the vaccination with the Recombinant Staphylococcus aureus vaccine within 6 months after the vaccination
Secondary Changes of the blood routine after vaccination. Changes of the blood routine after vaccination with the Recombinant Staphylococcus aureus vaccine on day 3, 7, 10, 14 and 17. day 0-17 after the vaccination
Secondary Changes of the blood biochemistry after vaccination. Changes of the blood biochemistry after vaccination with the Recombinant Staphylococcus aureus vaccine on day 3, 7, 10, 14 and 17. day 0-17 after the vaccination
Secondary Geometric mean titre against specific antigens Geometric mean titre measured at day 0, 7, 14, 21, 42 and month 3, 6. within 6 months after the vaccination
Secondary Geometric mean fold increase against specific antigens Geometric mean fold increase measured at day 7, 14, 21, 42 and month 3, 6. within 6 months after the vaccination
Secondary Positive conversion rate of serum against specific antigens Positive conversion rate of serum measured at day 7, 14, 21, 42 and month 3, 6. within 6 months after the vaccination
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04210505 - Nasal Decolonization of Dialysis Patients Noses Phase 4
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Completed NCT02282605 - Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects Phase 1/Phase 2
Recruiting NCT06319235 - Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® Phase 1/Phase 2
Enrolling by invitation NCT06317688 - Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis Phase 1
Withdrawn NCT02741869 - Photodisinfection for the Decolonization of Staphylococcus Aureus in Hemodialysis Patients N/A
Completed NCT03966040 - A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 1
Completed NCT04803708 - Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers Phase 1/Phase 2
Recruiting NCT05117398 - Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus Phase 3
Not yet recruiting NCT06456424 - Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection Phase 1/Phase 2
Completed NCT02820883 - A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Phase 0
Active, not recruiting NCT01879761 - Immune Resolution After Staphylococcus Aureus Bacteremia
Completed NCT01375621 - Livestock Contact and MRSA in Rural Areas
Recruiting NCT00532324 - Community-Acquired Methicillin Resistant Staphylococcus Aureus Colonization in Pregnant Women and Infections in Newborns N/A
Completed NCT04503252 - Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
Recruiting NCT06368856 - Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study Phase 1
Not yet recruiting NCT05899140 - Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial Phase 4
Completed NCT01792804 - Staphylococcus Aureus Bacteremia Antibiotic Treatment Options Phase 3
Enrolling by invitation NCT04897971 - Serum Based Diagnosis of and Monitoring of Infection Recovery in Orthopedic Spine Implant Infections
Completed NCT00572910 - A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED) Phase 2